Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02432651 · ClinicalTrials.gov registry record · Phase 1
Xanthohumol and Prevention of DNA Damage
A Phase 1 study, sponsored by Oregon State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT02432651 is a Phase 1 study that has completed, run by Oregon State University. The registered enrollment target is 64 participants.
The verdict
NCT02432651, a Phase 1 study, has completed, sponsored by Oregon State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The purpose of this research study is to learn if and in what amount a compound from hops, called xanthohumol (ZAN-tho-HUE-mol), prevents damage to DNA and oxidative stress. The human body is constantly exposed to oxidative stress from environmental compounds (e.g. air pollution) which may cause damage to DNA. The human body can repair some DNA damage, but too much DNA damage is harmful and may lead to cancer. Research done at OSU and around the world has shown that xanthohumol can stop or slow processes that lead to cancer.
Interventions
- DRUG Placebo
- DRUG 6 mg xanthohumol per day
- DRUG 12 mg xanthohumol per day
- DRUG 24 mg xanthohumol per day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02432651
The ClinicalTrials.gov registry entry for NCT02432651 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon State University, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02432651 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02432651 about?
NCT02432651 is a clinical study titled "Xanthohumol and Prevention of DNA Damage". The purpose of this research study is to learn if and in what amount a compound from hops, called xanthohumol (ZAN-tho-HUE-mol), prevents damage to DNA and oxidative stress. The human body is constantly exposed to oxidative stress from environmental compounds (e.g. air pollution) which may cause dam...
What is the current status of trial NCT02432651?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2015-03. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02432651?
The interventions under investigation include: Placebo (DRUG), 6 mg xanthohumol per day (DRUG), 12 mg xanthohumol per day (DRUG), 24 mg xanthohumol per day (DRUG).
Who is sponsoring clinical trial NCT02432651?
This trial is sponsored by Oregon State University, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.